Targeting Nanotechnologies for the Treatment of Thrombosis and Cardiovascular Disease.

abstract：:Severe acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins...

journal_title：Seminars in thrombosis and hemostasis

authors： Onorato D,Pucci M,Carpene G,Henry BM,Sanchis-Gomar F,Lippi G

更新日期：2021-01-22 00:00:00

abstract：:This study aimed to determine the impact of major hemorrhage (MH) protocol (MHP) activation on blood administration and patient outcome at a UK major cardiothoracic center. MH was defined in patients (> 16 years) as those who received > 5 units of red blood cells (RBCs) in < 4 hours, or > 10 units in 24 hours. Data we...

journal_title：Seminars in thrombosis and hemostasis

authors： Chang KW,Owen S,Gaspar M,Laffan M,Arachchillage DRJ

更新日期：2021-02-01 00:00:00

abstract：:The role of erythrocytes in thrombus formation has previously been regarded as passive by their influence on rheology. Erythrocytes are known, due to their abundance and size, to push platelets to the vascular wall (laminar shearing). This results in an increased platelet delivery at the vascular wall enabling platele...

journal_title：Seminars in thrombosis and hemostasis

authors： Du VX,Huskens D,Maas C,Al Dieri R,de Groot PG,de Laat B

更新日期：2014-02-01 00:00:00

abstract：:Although not reviewed during this session of the Workshop, other reactions in the hemostatic pathways are relevant to tumor-host cell interactions, are potential targets for antimetastatic agents, and are therefore included in Figure 1 and Table 1. For example, elsewhere in this issue of Seminars Loskutoff reviews the...

journal_title：Seminars in thrombosis and hemostasis

authors： Rickles FR,Hancock WW

更新日期：1988-01-01 00:00:00

abstract：:Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have bee...

journal_title：Seminars in thrombosis and hemostasis

authors： Severin T,Zieger B,Sutor AH

更新日期：2002-10-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Protein S is a vitamin K-dependent plasma glycoprotein circulating in plasma at a concentration of around 350 nM. Approximately 60% of protein S in human plasma is bound to the complement regulatory protein C4b-binding protein (C4BP) in a high-affinity, high-molecular-weight complex. Protein S in plasma has multiple a...

journal_title：Seminars in thrombosis and hemostasis

authors： Dahlbäck B

更新日期：2018-03-01 00:00:00

abstract：:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among m...

journal_title：Seminars in thrombosis and hemostasis

authors： Splichal JE,Stamm JA,Ornstein DL

更新日期：2003-06-01 00:00:00

abstract：:Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD). Unlike VWD, AVWS usually occurs in individuals with no personal or family history of bleeding. The prevalence of AVWS in the general population is unknown because d...

journal_title：Seminars in thrombosis and hemostasis

authors： Federici AB

更新日期：2011-02-01 00:00:00

abstract：:Arterial and venous thromboses are major contributors to coagulation-associated morbidity and mortality. Greater understanding of mechanisms leading to thrombus formation and stability is expected to lead to improved treatment strategies. Factor XIII (FXIII) is a transglutaminase found in plasma and platelets. During ...

journal_title：Seminars in thrombosis and hemostasis

authors： Byrnes JR,Wolberg AS

更新日期：2016-06-01 00:00:00

abstract：:The mechanism of thrombosis in patients with antiphospholipid syndrome is not clear. To investigate it, we examined the effect of monoclonal anticardiolipin (aCL) antibodies and beta2-glycoprotein I (beta2-GPI), which is required for formation of the aCL epitopes, on activated protein C (APC) and on fibrinolytic activ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Sawada KI,Koike T,Notoya A,Mukai M,Kohno M,Wada N,Itoh T,Yoshioka N

更新日期：1999-01-01 00:00:00

abstract：:The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial i...

journal_title：Seminars in thrombosis and hemostasis

authors： Niada R,Porta R,Pescador R,Mantovani M,Prino G

更新日期：1989-10-01 00:00:00

abstract：:Measurement of D-dimer (fibrin degradation product) is important for determining not only the activation of fibrinolysis but also the severity of a hypercoagulable state. However, fibrin degradation products are in variable, and the reactivity to cross-linked fibrin degradation products produced during fibrin degradat...

journal_title：Seminars in thrombosis and hemostasis

authors： Matsuo T,Kobayashi H,Kario K,Suzuki S

更新日期：2000-01-01 00:00:00

abstract：:The delicate biochemistry of coagulation and anticoagulation is greatly affected by deviations from the optimal temperature required for the interactions between various coagulation enzymes, cellular receptors, and intracellular mechanisms. Hyperthermia will lead to a prothrombotic state and, if sufficiently severe su...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2018-10-01 00:00:00

abstract：:The prothrombin time (PT) assay is the most clinically ordered coagulation test and is most often used for monitoring of vitamin K antagonist (VKA) therapy (e.g., warfarin), where results are expressed as an international normalized ratio (INR). The INR is in essence the patient's PT "mathematically adjusted" to a sta...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Adcock DM

更新日期：2008-10-01 00:00:00

abstract：:These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

journal_title：Seminars in thrombosis and hemostasis

authors： Hiebert L,Liu JM

更新日期：1991-01-01 00:00:00

abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

journal_title：Seminars in thrombosis and hemostasis

authors： Birgegard G

更新日期：2006-04-01 00:00:00

abstract：:Agonists of the estrogen receptor include estrogens and selective estrogen receptor modulators (SERMs). Both types of compounds increase the risk for thrombosis in the arterial and the venous tree. The magnitude of the effect is influenced by potency, which depends on the type of compound and the dose. The particulars...

journal_title：Seminars in thrombosis and hemostasis

authors： Artero A,Tarín JJ,Cano A

更新日期：2012-11-01 00:00:00

abstract：:Thrombotic diseases, as potentially induced by blood clots or vascular embolization, frequently occur with high rates of mortalities worldwide. Current drug thrombolysis, a primary clinical therapy, may increase fatal risk of hemorrhage when thrombolysis agents become systemically distributed. Given current thrombolys...

journal_title：Seminars in thrombosis and hemostasis

authors： Qu S,Ding X

更新日期：2020-07-01 00:00:00

abstract：:In this article, three cases, with antithrombin (AT) abnormality "Toyama" (type IIb), AT abnormality "Aomori" (type IIa), and congenital AT deficiency (type I) with pregnancy and delivery managed with administration of both AT concentrates and low-molecular-weight heparin, are described. Additionally, a case of AT-pro...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuragawa N

更新日期：1997-01-01 00:00:00

abstract：:In addition to the criteria of the Polycythemia Vera Study Group, positive markers for essential thrombocythemia (ET) include spontaneous BFU-E, splenomegaly, and megakaryocyte morphology in bone marrow smears and biopsy material. The hematologic features of 11 reported cases of ET in childhood showed platelet counts ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Van Genderen PJ

更新日期：1997-01-01 00:00:00

abstract：:We experienced 23 cases of venous thrombosis after gynecological surgery for the past 12 years at Tokyo Women's Medical University Hospital, representing 0.345 % of all patients. Eighteen of the 23 cases had deep venous thrombosis (DVT) including five cases followed by pulmonary embolism (PE), and five cases had PE wi...

journal_title：Seminars in thrombosis and hemostasis

authors： Adachi T,Nakabayashi M,Takeda Y

更新日期：1998-01-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:Platelets have classically been considered crucial effector cells in hemostasis, but now are increasingly recognized as players during inflammatory responses in innate and adaptive immunity. Platelets can recognize and kill invading pathogens, and, upon stimulation, also release a wide array of mediators that modify i...

journal_title：Seminars in thrombosis and hemostasis

authors： Kim SJ,Davis RP,Jenne CN

更新日期：2018-03-01 00:00:00

abstract：:There exist multiple clinical conditions, situations, and diseases in which persons appear to be at increased risk for thromboembolic phenomena, such as venous thrombosis and pulmonary embolus. Within this group of conditions, situations, or diseases, some are more clearly linked to thromboembolism that others. Simila...

journal_title：Seminars in thrombosis and hemostasis

authors： Kitchens CS

更新日期：1985-07-01 00:00:00

abstract：:This report describes the first two Japanese cases of AIDS developed in patients with hemophilia. One was a 48-year-old man with hemophilia B and the other was a 62-year-old patient with hemophilia A. They had nonspecific prodromal syndromes of AIDS initially, and later developed fatal opportunistic infections with Ca...

journal_title：Seminars in thrombosis and hemostasis

authors： Abe T,Kazama M,Kinoshita T,Matuda J,Yoshimura Y,Ryu T,Takahashi I

更新日期：1985-10-01 00:00:00

abstract：:D-dimer is the biochemical gold standard for diagnosing a variety of thrombotic disorders, but result reporting is heterogeneous in clinical laboratories. A specific five-item questionnaire was developed to gain a clear picture of the current standardization of D-dimer test results. The questionnaire was opened online...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Tripodi A,Simundic AM,Favaloro EJ

更新日期：2015-04-01 00:00:00

abstract：:C-type lectin-like receptor 2 (CLEC-2) has been identified on the surface of platelets as a receptor for a platelet activating snake venom, rhodocytin/aggretin. CLEC-2 belongs to a C-type lectin superfamily and binds to a sialoglycoprotein, podoplanin, in vivo. Platelets play a crucial role in hemostasis and thrombosi...

journal_title：Seminars in thrombosis and hemostasis

authors： Suzuki-Inoue K,Tsukiji N,Shirai T,Osada M,Inoue O,Ozaki Y

更新日期：2018-03-01 00:00:00

abstract：:The beta2-glycoprotein I (beta2-GPI) is known for its procoagulant as well as anticoagulant properties. The influence of beta2-GPI on tissue factor (TF) activity was investigated by chromogenic assays for both factor Xa generation and factor VIIa activity. When 1.36 mg/mL beta2-GPI was added to phospholipids prior to ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Yasukouchi T,Sawada KI,Koike T

更新日期：1998-01-01 00:00:00

abstract：:Immune thrombocytopenic purpura (ITP) is a bleeding disorder and is traditionally divided in acute and chronic forms based on the duration of the disease. Chronic ITP is characterized by a persistence of thrombocytopenia for more than 6 months. Ten to 20% of children with ITP and almost all adults will develop the chr...

journal_title：Seminars in thrombosis and hemostasis

authors： Kühne T,Imbach P

更新日期：1998-01-01 00:00:00